Graves' orbitopathy is the most common extrathyroidal manifestation of Graves' disease.
Up to now, curative treatment modalities for the most severe sight-threatening cases
have not been developed. Here the authors summarize the treatment protocol of Graves'
orbitopathy and review novel therapeutic options. They review the literature on this
topic and present their own clinical experience. The authors point out that anti-CD20
antibody could positively influence the clinical course of Graves' orbitopathy. Selenium
is efficient in mild cases. Further prospective investigations are warranted. Orv.
Hetil., 2014, 155(33), 1295-1300.
